Page last updated: 2024-09-05

erlotinib hydrochloride and Mouth Neoplasms

erlotinib hydrochloride has been researched along with Mouth Neoplasms in 17 studies

Research

Studies (17)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (17.65)	29.6817
2010's	12 (70.59)	24.3611
2020's	2 (11.76)	2.80

Authors

Authors	Studies
Chan, CY; Chang, CM; Chen, YH; Hong, SC; Huang, CY; Liao, PC	1
Dave, H; Hariharan, K; Mehta, T; Omri, A; Sami, A; Shah, J	1
Abraham, G; Banavali, S; Bhattacharjee, A; Chandrasekharan, A; Das, S; Dhumal, S; DSouza, H; Gota, V; Joshi, A; Kashyap, L; Kumar, S; Mahajan, A; Mahimkar, M; Menon, N; Mukadam, S; Nawale, K; Noronha, V; Pandey, M; Patil, VM; Prabhash, K; Sable, N; Simha, V; Solanki, B; Srinivas, S; Talreja, V	1
Gourd, E	1
Liu, J; Xie, A	1
Cheong, SC; Fadlullah, MZH; Gan, CP; Kelly, GM; Lee, BKB; Lee, HM; Patel, V; Yee, PS; Zainal, NS	1
Bothwell, KD; Hershberger, PA; Johnson, CS; Kuriakose, MA; Merzianu, M; Seshadri, M; Shaurova, T; Suresh, A	1
Blair, EA; Boyle, JO; Cohen, EE; El-Naggar, A; Gillenwater, AM; Gutkind, JS; Heymach, JV; Kim, ES; Lee, JJ; Lin, HY; Lingen, MW; Lippman, SM; Mao, L; Martin, JW; Meiller, T; Myers, J; Papadimitrakopoulou, V; Saintigny, P; Shin, DM; Shinn, N; Tang, X; Vigneswaran, N; William, WN; Wistuba, II	1
Bauman, JE; Grandis, J	1
Printz, C	1
Ambrosetti, D; Benhamou, Y; Brolih, S; Chamorey, E; Lo Nigro, C; Merlano, M; Monteverde, M; Pagès, G; Picco, V; Raybaud, H; Sudaka, A	1
Bednash, JS; Freilino, ML; Gooding, WE; Grandis, JR; Joyce, SC; Leeman-Neill, RJ; Lingen, MW; Neill, DB; Panahandeh, MC; Seethala, RR; Singh, SV; Thomas, SM	1
Baumeister, P; Harréus, U; Heinrich, K; Märte, M; Reiter, M; Schwenk-Zieger, S	1
Chen, X; Duvvuri, U; Fung, C; Grandis, JR	1
Nelson, NJ	1
Couzin, J	1
Chandra, NR; Efferth, T; Gebhart, E; Konkimalla, VB; Suhas, VL	1

Reviews

2 review(s) available for erlotinib hydrochloride and Mouth Neoplasms

Article	Year
Chemoprevention of oral cancer in leukoplakia patients: A systematic review and meta-analysis. JPMA. The Journal of the Pakistan Medical Association, 2017, Volume: 67, Issue:9 Topics: Antineoplastic Agents; beta Carotene; Chemoprevention; Erlotinib Hydrochloride; Humans; Isotretinoin; Leukoplakia, Oral; Mouth Neoplasms; Precancerous Conditions; Provitamins; Tea; Treatment Outcome; Vitamin A; Vitamins	2017
Diagnosis and therapy of oral squamous cell carcinoma. Expert review of anticancer therapy, 2007, Volume: 7, Issue:3 Topics: Age Factors; Alcohol Drinking; Antineoplastic Agents; Aporphines; Azo Compounds; Berberine; Carcinoma, Squamous Cell; Chromosome Aberrations; Crystallography, X-Ray; Databases, Factual; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Mouth Neoplasms; Neoplasm Proteins; Nucleic Acid Hybridization; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Smoking; Stilbenes; Structure-Activity Relationship	2007

Article

Year

Chemoprevention of oral cancer in leukoplakia patients: A systematic review and meta-analysis.

JPMA. The Journal of the Pakistan Medical Association, 2017, Volume: 67, Issue:9

Topics: Antineoplastic Agents; beta Carotene; Chemoprevention; Erlotinib Hydrochloride; Humans; Isotretinoin; Leukoplakia, Oral; Mouth Neoplasms; Precancerous Conditions; Provitamins; Tea; Treatment Outcome; Vitamin A; Vitamins

2017

Diagnosis and therapy of oral squamous cell carcinoma.

Expert review of anticancer therapy, 2007, Volume: 7, Issue:3

Topics: Age Factors; Alcohol Drinking; Antineoplastic Agents; Aporphines; Azo Compounds; Berberine; Carcinoma, Squamous Cell; Chromosome Aberrations; Crystallography, X-Ray; Databases, Factual; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Mouth Neoplasms; Neoplasm Proteins; Nucleic Acid Hybridization; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Smoking; Stilbenes; Structure-Activity Relationship

2007

Trials

2 trial(s) available for erlotinib hydrochloride and Mouth Neoplasms

Article	Year
Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 11-10, Volume: 37, Issue:32 Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Male; Methotrexate; Middle Aged; Mouth Neoplasms; Organoplatinum Compounds; Progression-Free Survival; Squamous Cell Carcinoma of Head and Neck	2019
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA oncology, 2016, Volume: 2, Issue:2 Topics: Administration, Oral; Anticarcinogenic Agents; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Loss of Heterozygosity; Male; Middle Aged; Mouth Neoplasms; Precancerous Conditions; Prospective Studies; Protein Kinase Inhibitors; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States	2016

Article

Year

Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 11-10, Volume: 37, Issue:32

Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Male; Methotrexate; Middle Aged; Mouth Neoplasms; Organoplatinum Compounds; Progression-Free Survival; Squamous Cell Carcinoma of Head and Neck

2019

Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.

JAMA oncology, 2016, Volume: 2, Issue:2

Topics: Administration, Oral; Anticarcinogenic Agents; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Loss of Heterozygosity; Male; Middle Aged; Mouth Neoplasms; Precancerous Conditions; Prospective Studies; Protein Kinase Inhibitors; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States

2016

Other Studies

13 other study(ies) available for erlotinib hydrochloride and Mouth Neoplasms

Article	Year
Oral Squamous Cell Carcinoma Cells with Acquired Resistance to Erlotinib Are Sensitive to Anti-Cancer Effect of Quercetin via Pyruvate Kinase M2 (PKM2). Cells, 2023, 01-01, Volume: 12, Issue:1 Topics: Animals; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glucose; Head and Neck Neoplasms; Humans; Lung Neoplasms; Mice; Mouth Neoplasms; Pyruvate Kinase; Quercetin; Squamous Cell Carcinoma of Head and Neck	2023
Localized delivery of Erlotinib using liposomal gel formulations for the treatment of oral squamous cell carcinoma. International journal of pharmaceutics, 2023, Jul-25, Volume: 642 Topics: Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Liposomes; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck	2023
Metronomic chemotherapy option for advanced oral cancer. The Lancet. Oncology, 2019, Volume: 20, Issue:11 Topics: Administration, Metronomic; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Humans; Methotrexate; Mouth Neoplasms; Progression-Free Survival	2019
The 4717C > G polymorphism in periplakin modulates sensitivity to EGFR inhibitors. Scientific reports, 2019, 02-20, Volume: 9, Issue:1 Topics: Biomarkers, Pharmacological; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Genotype; Humans; Mouth Neoplasms; Phosphorylation; Plakins; Polymorphism, Single Nucleotide; Quinazolines; Signal Transduction	2019
Impact of Short-term 1,25-Dihydroxyvitamin D3 on the Chemopreventive Efficacy of Erlotinib against Oral Cancer. Cancer prevention research (Philadelphia, Pa.), 2015, Volume: 8, Issue:9 Topics: 4-Nitroquinoline-1-oxide; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Calcitriol; Carcinogens; Carcinoma, Squamous Cell; Disease Progression; Down-Regulation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Mice, SCID; Mouth Neoplasms; Neoplasm Transplantation; Quinolones	2015
Oral Cancer Chemoprevention--The End of EPOC, the Beginning of an Epoch of Molecular Selection. JAMA oncology, 2016, Volume: 2, Issue:2 Topics: Anticarcinogenic Agents; Erlotinib Hydrochloride; Female; Humans; Male; Mouth Neoplasms; Precancerous Conditions; Protein Kinase Inhibitors	2016
Developments in precision medicine: Studies highlight new applications for cancer chemoprevention, treatment. Cancer, 2016, Mar-01, Volume: 122, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemoprevention; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Humans; Loss of Heterozygosity; Mouth Neoplasms; Precancerous Conditions; Precision Medicine	2016
Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinoma. Oncotarget, 2016, Jul-12, Volume: 7, Issue:28 Topics: Animals; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Mouth Neoplasms; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Telomeric Repeat Binding Protein 2; Tumor Microenvironment; Xenograft Model Antitumor Assays	2016
Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemically-induced mouse model of oral squamous cell carcinoma. Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:2 Topics: 4-Nitroquinoline-1-oxide; Animal Feed; Animals; Carcinogens; Carcinoma, Squamous Cell; Commiphora; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Immunoenzyme Techniques; Mice; Mice, Inbred CBA; Mouth Neoplasms; Plant Extracts; Plant Gums; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; STAT3 Transcription Factor	2011
The impact of EGFR stimulation and inhibition on BPDE induced DNA fragmentation in oral/oropharyngeal mucosa in vitro. Oral oncology, 2011, Volume: 47, Issue:12 Topics: 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Case-Control Studies; Cetuximab; Cisplatin; DNA Damage; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Oropharyngeal Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tumor Necrosis Factor-alpha; Up-Regulation; Young Adult	2011
EGFR tyrosine kinase inhibition induces autophagy in cancer cells. Cancer biology & therapy, 2012, Volume: 13, Issue:14 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; HeLa Cells; Humans; Lung Neoplasms; Mouth Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; RNA Interference; RNA, Small Interfering; Sirolimus; Ubiquitin-Activating Enzymes	2012
Years of research come to fruition with launch of oral cancer prevention trial. Journal of the National Cancer Institute, 2006, Jan-18, Volume: 98, Issue:2 Topics: Animals; Antineoplastic Agents; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Membrane Proteins; Mouth Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Receptor Cross-Talk; Signal Transduction; Sulfonamides	2006
Cancer research. Fake data, but could the idea still be right? Science (New York, N.Y.), 2006, Jul-14, Volume: 313, Issue:5784 Topics: Aneuploidy; Antineoplastic Agents; Controlled Clinical Trials as Topic; Erlotinib Hydrochloride; Genetic Markers; Humans; Loss of Heterozygosity; Mouth Diseases; Mouth Neoplasms; Quinazolines; Risk Factors; Scientific Misconduct	2006